(Q38881484)

7 September 2017

Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial (English)

1 reference

7 September 2017

0 references

0 references

Plasmodium falciparum

0 references

5

Grant Dorsey

1 reference

7 September 2017

3

Moses R Kamya

1 reference

7 September 2017

6

Philip J Rosenthal

1 reference

7 September 2017

1

Sarah G Staedke

1 reference

7 September 2017

Arthur Mpimbaza

2

1 reference

PubMed ID

15567011

7 September 2017

Bridget K Nzarubara

series ordinal

4

1 reference

PubMed ID

15567011

7 September 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

7 September 2017

1 reference

7 September 2017

364

1 reference

7 September 2017

1950-1957

1 reference

7 September 2017

9449

1 reference

Averting a malaria disaster

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Increasing antimalarial drug resistance in Uganda and revision of the national drug policy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

The assessment of antimalarial drug efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Changing the first line drug for malaria treatment--cost-effectiveness analysis with highly uncertain inter-temporal trade-offs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Prevention of Increasing Rates of Treatment Failure by Combining Sulfadoxine‐Pyrimethamine with Artesunate or Amodiaquine for the Sequential Treatment of Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

How frequent are notified severe cutaneous adverse reactions to Fansidar?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917478-3

7 January 2021

10.1016/S0140-6736(04)17478-3

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

15567011